Latest 10-K annual reports
NASDAQ
Ultra Clean Holdings, Inc. reported a net loss of $181.2 million for fiscal year 2025, primarily due to a significant goodwill impairment charge and a slight revenue decline.
NASDAQ
IBRX
Immunitybio, INCImmunityBio reports significant revenue growth and multiple international approvals for its lead immunotherapy ANKTIVA, while navigating substantial operating losses, ongoing legal disputes, and the need for additional financing.
NYSE
Hims & Hers Health, Inc. announced significant revenue and Adjusted EBITDA growth for 2025, alongside international expansion and new product launches, but faces increasing regulatory and legal challenges.
NYSE
OVV
Ovintiv INCOvintiv Inc. reported net earnings of $1,242 million for fiscal year 2025, driven by strategic acquisitions and operational efficiencies, while navigating lower oil prices and divesting non-core assets.
NYSE
ACVA
Acv Auctions INCACV Auctions Inc. announced significant revenue growth and a more than doubling of Adjusted EBITDA in its 2025 annual report, despite a net loss and a substantial charge from a dealer bankruptcy.
NYSE
BWX Technologies, Inc. announced significant revenue and operating income growth in 2025, driven by strategic acquisitions and increased demand in both Government and Commercial Operations segments.
NASDAQ
Mattel's 2025 full-year results fell below expectations with a 1% net sales decrease and a 27% drop in net income, despite strategic cost savings and a new $1.5 billion share repurchase authorization.
NASDAQ
Axsome Therapeutics achieved significant revenue growth in 2025, driven by commercial product sales, while advancing its robust CNS pipeline with key regulatory milestones and new acquisitions.
NASDAQ
The Cheesecake Factory reports a 4.7% revenue increase in fiscal 2025, driven by new restaurant openings, while managing inflationary pressures and debt.
NASDAQ
NOVT
Novanta INCNovanta Inc. reported a 3.3% revenue increase to $980.6 million in 2025, but operating income and EPS declined significantly due to increased expenses and restructuring costs, while bolstering liquidity with a $613.1 million equity unit issuance.
NYSE
Brandywine Realty Trust reported a net loss of $178.9 million for 2025, driven by significant impairment charges and increased interest expenses, despite slight improvements in core property occupancy.
NYSE
Transocean Ltd. reported a significant net loss of $2.915 billion for 2025, driven by $3.05 billion in asset impairments, while announcing a major business combination with Valaris Limited.
NYSE
RYN
Rayonier INCRayonier Inc. finalized its merger with PotlatchDeltic, significantly expanding its timberland and entering wood products manufacturing, while reporting a substantial gain from the New Zealand joint venture sale.
NASDAQ
LPL Financial reports a significant increase in total revenue and assets driven by strategic acquisitions, despite a decrease in net income for the fiscal year ended December 31, 2025.
NASDAQ
Kratos Defense & Security Solutions, Inc. announced significant revenue increases and strategic investments in key defense technologies, alongside a major debt extinguishment and new credit facility.
NYSE
Quaker Houghton reported a net loss of $2.5 million for 2025, primarily due to an $88.8 million goodwill impairment charge in its EMEA segment, despite a 3% increase in net sales driven by acquisitions.
NYSE
LAZ
Lazard, INCLazard, Inc. reported a 2% increase in net revenue for 2025, driven by growth in both Financial Advisory and Asset Management, despite a decline in net income.
NYSE
ProAssurance Corporation reported improved operating and combined ratios for 2025, driven by significant favorable reserve development, as it progresses towards a cash acquisition by The Doctors Company.
Blackboxstocks Inc. files its 2025 Annual Report, detailing a pending merger with REalloys Inc., ongoing operational losses, and strategic product expansions.
NYSE
ManpowerGroup reported a significant net loss and operating profit decline in 2025, despite slight revenue growth, driven by goodwill impairments and restructuring costs.
NYSE
Easterly Government Properties, Inc. announced its 2025 annual results, highlighting revenue growth from strategic acquisitions and development completions, alongside increased debt and an executive severance plan.
NASDAQ
Erie Indemnity Company reported a 6.8% decrease in net income for 2025, despite an 8.9% increase in premiums written by the Erie Insurance Exchange, while facing ongoing litigation over management fees.
NYSE
COUR
Coursera, INCCoursera reported a 9% revenue increase to $757.5 million in 2025, narrowing its net loss, and announced progress on its merger with Udemy, anticipated to close by late 2026.
NASDAQ
Martin Midstream Partners L.P. reports a net loss of $14.7 million for fiscal year 2025, navigating volatile commodity markets and strategic shifts in its diverse Gulf Coast operations.
NYSE
MediaAlpha, Inc. reported robust financial performance for 2025, driven by significant growth in its P&C insurance vertical, while also finalizing a $45 million settlement with the FTC.
NASDAQ
WEN
Wendy's COWendy's reported a challenging 2025 with declines in global systemwide sales and U.S. same-restaurant sales, despite growth in international markets and digital channels, as it progresses with its 'Project Fresh' strategic plan.
NASDAQ
BOOM
Dmc Global INCDMC Global Inc. reported a 5% decrease in consolidated net sales for 2025, primarily driven by lower performance in its DynaEnergetics and NobelClad segments, while net debt significantly improved.
NYSE
Apple Hospitality REIT reports a slight decline in RevPAR and net income for 2025 amidst macroeconomic uncertainty, while strategically acquiring new properties and extending its share repurchase program.
Great Lakes Dredge & Dock Corporation reported a significant increase in 2025 revenues and net income, driven by strong domestic capital and coastal protection projects, while also announcing a pending merger with Saltchuk Resources, Inc. at $17.00 per share.
NASDAQ
ORIC Pharmaceuticals reports significant clinical progress for rinzimetostat and enozertinib, alongside successful capital raises, as it focuses on overcoming cancer resistance.